These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27716652)

  • 1. Red blood cell distribution width is a survival predictor beyond anemia and Nt-ProBNP in stable optimally medicated heart failure with reduced ejection fraction outpatients.
    Sargento L; Simões AV; Longo S; Lousada N; Palma Dos Reis R
    Clin Hemorheol Microcirc; 2017; 65(2):185-194. PubMed ID: 27716652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of prognostic value of red cell distribution width and NT-proBNP for short-term clinical outcomes in acute heart failure patients.
    He W; Jia J; Chen J; Qin S; Tao H; Kong Q; Xue Q; Zhang D
    Int Heart J; 2014; 55(1):58-64. PubMed ID: 24463920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of red cell distribution width and other red cell parameters in patients with chronic heart failure during two years of follow-up.
    Wołowiec Ł; Rogowicz D; Banach J; Buszko K; Surowiec A; Błażejewski J; Bujak R; Sinkiewicz W
    Kardiol Pol; 2016; 74(7):657-64. PubMed ID: 26779853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of RDW alone and in combination with NT-proBNP in patients with heart failure.
    Liang L; Huang L; Zhao X; Zhao L; Tian P; Huang B; Feng J; Zhang J; Zhang Y
    Clin Cardiol; 2022 Jul; 45(7):802-813. PubMed ID: 35621296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red blood cell distribution width and its relation to cardiac function and biomarkers in a prospective hospital cohort referred for echocardiography.
    Holmström A; Sigurjonsdottir R; Hammarsten O; Gustafsson D; Petzold M; Fu ML
    Eur J Intern Med; 2012 Oct; 23(7):604-9. PubMed ID: 22939804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Values of Red Blood Cell Distribution Width in Assessing Severity of Chronic Heart Failure.
    Liu S; Wang P; Shen PP; Zhou JH
    Med Sci Monit; 2016 Jun; 22():2119-25. PubMed ID: 27324271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
    Suzuki S; Sugiyama S
    Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
    JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of Red Cell Volume Distribution Width and N-Terminal Pro-Brain Natriuretic Peptide with Severity and Prognosis of Patients with Acute Coronary Syndrome Receiving Percutaneous Coronary Intervention.
    Pan R
    Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy.
    D'Amato R; Tomberli B; Castelli G; Spoladore R; Girolami F; Fornaro A; Caldini A; Torricelli F; Camici P; Gensini GF; Cecchi F; Olivotto I
    Am J Cardiol; 2013 Oct; 112(8):1190-6. PubMed ID: 23871673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of the Red Blood Cell Distribution Width Improves the Risk Prediction in Cardiac Resynchronization Therapy.
    Boros AM; Perge P; Jenei Z; Karády J; Zima E; Molnár L; Becker D; Gellér L; Prohászka Z; Merkely B; Széplaki G
    Dis Markers; 2016; 2016():7304538. PubMed ID: 26903690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure.
    Corell P; Gustafsson F; Kistorp C; Madsen LH; Schou M; Hildebrandt P
    Int J Cardiol; 2007 May; 117(3):395-402. PubMed ID: 16919342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.